In the United States – the world’s biggest and most advanced pharmaceutical market – of the 46 new drugs given consent for marketing by regulators last year, 28 were developed by US firms and the realisation of all but four of the rest were led by European firms. None were Chinese.
China’s big ambitions to become a powerhouse of pharmaceutical innovation is as much about the well-being of its people as it is about narrowing the gap with the West.
Read more